Form D · Pharmaceuticals
ACTINOBAC BIOMED, INC.
Kendall Park, NJ · CIK 0001712650
Offering snapshot reported Jun 8, 2018 · SEC filing
- Reported sold
- $1M Offering amount: $6M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 29, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 8, 2018 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| Jul 24, 2017 | Initial | $2,400,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-314161
Source: Form D, filed Jun 8, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Alff | Director |
| Benjamin Belinka | Director, Executive |
| Benjamin Belinka, Jr. | Director, Executive |
| James Golubieski | Director |
| Scott Kachlany | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
15 Pelham Rd
Kendall Park, NJ, 08824
Kendall Park, NJ, 08824